Brickell Biotech (BBI) Announces Proposed Underwritten Public Offering of Common Stock

Brickell Biotech, Inc. (Nasdaq: BBI) (“Brickell”), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatologic, autoimmune and other debilitating diseases, announced today that it has commenced a proposed underwritten public offering of shares of its common stock. In connection with this offering, Brickell expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock at the public offering price, less the underwriting discount. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Brickell intends to use the net proceeds of this offering for research and development, including clinical trials, working capital, business development and general corporate purposes.

William Blair & Company, L.L.C. and Oppenheimer & Co. Inc. are acting as joint book-running managers for the offering.

You May Also Be Interested In

• Gryphon Digital Mining (GRYP) Enters $70M ATM Agreement
• EHang Holdings (EH) Files Mixed Shelf
• HUB Cyber Security (HUBC) Strongly Responds To Dominion’s Misleading Lawsuit; Reaffirms Dedication To Expansion And Worldwide Customer Support